MedPath

Establishing Global Reference Values for Human Milk

Conditions
Human Milk Nutrient Reference Values
Interventions
Other: Assessment of human milk nutrient composition
Registration Number
NCT03254329
Lead Sponsor
USDA, Western Human Nutrition Research Center
Brief Summary

The primary purpose of the proposed research is to establish Reference Values (RVs) for micronutrients (MN) and macronutrients in human milk. The investigators' research to date has revealed highly variable milk MN concentrations among populations, and very low values in some low income countries (LICs) likely caused by poor maternal status and/or diet but RVs are needed to interpret these values. During the past year the investigators conducted a review of human milk nutrient composition, and formed a Technical Advisory Group (TAG) which developed the current proposal. Here, the investigators are conducting a longitudinal project on well-nourished women and infants. The Mothers, Infants and Lactation Quality (MILQ) study is a multi-center cohort project, investigating breast milk nutrient composition in well-nourished women across the first 8.5 months of lactation in four different populations. The countries involved are Denmark, Brazil, Bangladesh and The Gambia. Exclusive breastfeeding is an eligibility criterion up until the second post-partum study visit (between 1 - 3.4 months postpartum), with the exception of the first week after delivery. Other data collected on mothers and infants, including maternal and infant nutrient intake and status, morbidity, milk volume, and infant development, will inform interpretation and support application of the results. While the priority is to develop RVs for MN, other analyses will include human milk oligosaccharides (HMOs) and proteins, and free amino acids (FAA) in infant plasma. Thus, with the samples obtained the investigators will perform (a) laboratory analyses of milk, plasma and urine nutrients to construct RVs for global application, (b) analyses of HMOs and proteins in milk, and (c) metabolomic analysis of FAA and other metabolites in infant plasma. By request of the Bill and Melinda Gates Foundation (BMGF), colostrum and fecal microbiota samples will also be collected and stored for later analyses.

Detailed Description

The investigators will collect breast milk samples at four visits, at 2-3 days after birth (colostrum) and at 1-3.4, 3.5-5.9, and 6-8.5 months of lactation from well-nourished mothers age ≥18 to ≤40 years, in a systematic, identical way in four countries. The four sites are: Copenhagen, Denmark; Banjul, The Gambia; Rio de Janeiro, Brazil; and Mirpur, Dhaka, Bangladesh. The most important site selection criteria were that multiple micronutrient supplements are not consumed after week 28 of pregnancy; maternal diet is adequate but consumption of highly fortified foods is limited; and exclusive breastfeeding is 60% at 4 months.

In order to have 250 women and infants per site complete the study at 8.5 months, approximately 500 women will be recruited during the third trimester of pregnancy. This should allow for mothers and infants not meeting study eligibility criteria in pregnancy or early lactation, and drop-outs from the study. Recruitment during pregnancy will increase the opportunity to locate and recruit women since recruitment in the immediate post-delivery period will be difficult. It will also enable the women to be counselled on the importance of exclusive breastfeeding (EBF). Colostrum will be collected at 2-3 days postpartum for future analysis. The first collection of mature milk will occur between 1 and 3.4 months postpartum, when maternal and infant blood samples will also be collected on all participants. At the final two visits, in addition to milk collection, blood will be taken from all mothers but only half of the infants each time, primarily for the assessment of micronutrient status.

A requirement is that infants must be EBF in the 1-3.4 month period, and breastfed (BF) in the second and third period. Longitudinal measurements on the same mother after the BF period are not necessary for statistical reasons, as the investigators are not creating RVs for change in milk composition. The investigators expect that due to attrition and cessation of BF, the sample size will need to be augmented in later months; the alternative would have been to recruit and measure many more women in earlier stages in order to have an adequate sample size in the 7-8.5 month interval, which would be a much less efficient approach. Therefore after 6 months, if women are not breastfeeding, additional lactating women will be recruited from the group that was not EBF in the 3.4 month period, or from the local health center or community.

At all three points of mature milk collection the investigators will measure breast milk volume; diet, anthropometry and morbidity of the mother and infant; and infant development at 3.5-5.9 and 6 to 8.5 months; and will collect infant fecal samples for future analyses of the microbiome. Milk volume will be measured at three sites using the International Atomic Energy Agency's protocol that requires dosing the mother with deuterated water and collecting maternal and infant saliva urine samples at 0, 1, 2, 3, 4, 13 and 14 days after the dose. In Denmark breast milk volume will be measured by 24 hour infant weighing.

Most of the laboratory analyses will be conducted at the United States Department of Agriculture, Agricultural Research Service, Western Human Nutrition Research Center (WHNRC) in Davis, California. Other analyses will be performed in the Department of Chemistry at University of California, Davis (HMOs and other bioactive compounds in milk), and the Swiss Federal Institute of Technology in Zurich (iodine status). RVs will be constructed following the methods and principles developed for the World Health Organization (WHO) Child Growth Standards and the Intergrowth-21st Project.

An add-on study "Evaluation of maternal insulin resistance, metabolic and inflammatory biomarkers for prediction of successful initiation and duration of breastfeeding" is being conducted at the Danish site and was approved by The Regional Committee on Health Research Ethics with (H-17015174).

The aims of the add-on study are to evaluate if maternal metabolic and inflammatory biomarkers can predict successful initiation and duration of breastfeeding in a population of healthy non-obese Danish women, to evaluate the impact of maternal inflammatory biomarkers during pregnancy on the offspring's growth and risk factors for later disease, and to relate the impact of maternal metabolic and inflammatory biomarkers during pregnancy on breastfeeding behavior and on the offspring's growth and risk factors for later disease in this population to corresponding outcomes in an established cohort of infants born of obese mothers.

Recruitment & Eligibility

Status
UNKNOWN
Sex
Female
Target Recruitment
2000
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
BangladeshAssessment of human milk nutrient compositionAssessment of human milk nutrient composition. Approximately 500 women and their infants recruited, 250 dyads completing study
DenmarkAssessment of human milk nutrient compositionAssessment of human milk nutrient composition. Approximately 500 women and their infants recruited, 250 dyads completing study
BrazilAssessment of human milk nutrient compositionAssessment of human milk nutrient composition. Approximately 500 women and their infants recruited, 250 dyads completing study
The GambiaAssessment of human milk nutrient compositionAssessment of human milk nutrient composition. Approximately 500 women and their infants recruited, 250 dyads completing study
Primary Outcome Measures
NameTimeMethod
Change in vitamin and mineral concentrations in human breast milkBreast milk samples collected 1-3.4, 3.5-5.9, and 6-8.5 months postpartum

To establish reference values, the vitamin and mineral concentrations will be measured in milk of well-nourished women

Secondary Outcome Measures
NameTimeMethod
Milk iodine1-3.4, 3.5-5.9, and 6-8.5 months postpartum

Milk iodine

Maternal weight1-3.4, 3.5-5.9, and 6-8.5 months postpartum

Measure of weight in kilograms (kg)

Infant weight1-3.4, 3.5-5.9, and 6-8.5 months

Measure of weight in grams (g) or kilograms (kg)

Maternal height1-3.4, 3.5-5.9, and 6-8.5 months postpartum

measured in centimeters (cm)

Variation in other constituents of human breast milkBreast milk samples collected at 1-3.4, 3.5-5.9, and 6-8.5 months postpartum

Macronutrients, and human milk oligosaccharides and proteins will be analyzed

Maternal and infant iodine status1-3.4, 3.5-5.9, and 6-8.5 months postpartum

Urinary iodine; thyroid stimulating hormone, thyroglobulin and thyroxine in dried blood spots

Maternal nutrient intake1-3.4, 3.5-5.9, and 6-8.5 months postpartum

Assessment of dietary intake by two days 24-hour recall

Infant dietary habits1-3.4, 3.5-5.9, and 6-8.5 months

Assessment of dietary intake by diet habits questionnaire

Infant morbidity1-3.4, 3.5-5.9, and 6-8.5 months

Data collected from mothers on infant health

Maternal lipid panelMeasured once at gestational week 28-30

In Denmark only, a serum sample will be collected and stored for measurement of a lipid profile including Total Cholesterol, High Density Lipoprotein-cholesterol, Low Density Lipoprotein-cholesterol, Very Low Density Lipoprotein-cholesterol, and Triglycerides in mmol/l).

Micronutrient status of mothers and infantsBlood and urine samples surveyed at 1-3.4, 3.5-5.9, and 6-8.5 months postpartum

Vitamin and mineral status of mothers and infants will be assessed in blood and urine

Maternal nutrient intake during pregnancyMeasured during gestational week 35-37

Assessment of dietary intake by two days 24-hour recall in Denmark and Brazil

Maternal inflammatory markersMeasured once at gestational week 28-30

In Denmark only, a serum sample will be collected and stored for measurement of high sensitivity C-reactive protein (mg/l).

Milk volume1-3.4, 3.5-5.9, and 6-8.5 months postpartum

Measurements of usual daily milk volume using deuterated water or, in Denmark, 24 hour infant weighing

Infant nutrient intake1-3.4, 3.5-5.9, and 6-8.5 months

Assessment of dietary intake by two days 24-hour recall of the infant's diet

Infant length1-3.4, 3.5-5.9, and 6-8.5 months

measured in cm

Maternal body mass index1-3.4, 3.5-5.9, and 6-8.5 months postpartum

Maternal weight and height will be combined to determine body mass index (kg/m2)

Infant body composition1-3.4, 3.5-5.9, and 6-8.5 months

Assessment of body composition by Air Displacement Plethysmography, in The Gambia, and by bioimpedance in Denmark and Brazil.

Infant development6-8.5 months

Ages and Stages questionnaire

Change in infant microbiome1-3.4, 3.5-5.9, and 6-8.5 months

DNA analyses of infant gut bacteria derived from fecal samples

Change in maternal microbiomeCollected at gestational week 28-40, and 1-3.4, 3.5-5.9, and 6-8.5 months postpartum

DNA analyses of maternal gut bacteria derived from fecal samples in The Gambia and Brazil only

Maternal markers of insulin sensitivityMeasured once at gestational week 28-30

In Denmark only, a serum sample will be collected and stored for measurement of insulin (mU/l), c-peptide (pmol/l), and leptin (ng/l)

Infant growth1-3.4, 3.5-5.9, and 6-8.5 months postpartum

Infant weight and length will be aggregated to determine infant growth status

Maternal body composition1-3.4, 3.5-5.9, and 6-8.5 months postpartum

Assessment of body composition by bioimpedance in Denmark, The Gambia, and Brazil only.

Infant motor development3.5-5.9 and 6-8.5 months

Infant motor development measured using a World Health Organization (WHO) assessment of motor milestones

Maternal Glucose ToleranceMeasured once at gestational week 28-30

In Denmark only, an Oral Glucose Tolerance Test will be performed. Fasting blood sugar (BS), and BS at 1 and 2 hours after glucose beverage.

Maternal Hemoglobin A1c (HbA1c)Measured once at gestational week 28-30

In Denmark only, maternal Hemoglobin A1c will be measured in whole blood

Trial Locations

Locations (4)

International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b)

🇧🇩

Dhaka, Bangladesh

Federal University of Rio de Janeiro

🇧🇷

Rio de Janeiro, Brazil

Medical Research Council Gambia

🇬🇲

Bakau, Kombo Saint Mary's, Gambia

University of Copenhagen

🇩🇰

Copenhagen, Frederiksberg, Denmark

© Copyright 2025. All Rights Reserved by MedPath